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Abstract
Background: Alcohol Use Disorder is a highly prevalent mental disorder which puts a severe burden on individuals,
families, and society. The treatment of Alcohol Use Disorder is challenging and novel and innovative treatment
approaches are needed to expand treatment options. A promising neuroscience-based intervention method that
allows targeting cortical as well as subcortical brain processes is real-time functional magnetic resonance imaging
neurofeedback. However, the efficacy of this technique as an add-on treatment of Alcohol Use Disorder in a
clinical setting is hitherto unclear and will be assessed in the Systems Biology of Alcohol Addiction (SyBil-AA)
neurofeedback study.
Methods: N = 100 patients with Alcohol Use Disorder will be randomized to 5 parallel groups in a single-blind
fashion and receive real-time functional magnetic resonance imaging neurofeedback while they are presented
pictures of alcoholic beverages. The groups will either downregulate the ventral striatum, upregulate the right
inferior frontal gyrus, negatively modulate the connectivity between these regions, upregulate, or downregulate
the auditory cortex as a control region. After receiving 3 sessions of neurofeedback training within a maximum of
2 weeks, participants will be followed up monthly for a period of 3 months and relapse rates will be assessed as
the primary outcome measure.
Discussion: The results of this study will provide insights into the efficacy of real-time functional magnetic resonance
imaging neurofeedback training in the treatment of Alcohol Use Disorder as well as in the involved brain systems. This
might help to identify predictors of successful neurofeedback treatment which could potentially be useful in developing
personalized treatment approaches.
Trial registration: The study was retrospectively registered in the German Clinical Trials Register (trial identifier:
DRKS00010253; WHO Universal Trial Number (UTN): U1111–1181-4218) on May 10th, 2016.
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Background
Alcohol use disorder (AUD) is characterized by drinking
of alcohol despite negative or harmful consequences, a
loss of control over drinking behavior, the development
of craving for alcohol, and the occurrence of withdrawal
symptoms. AUD puts a severe burden on individuals,
families, and societies [1] and is highly prevalent in western
countries with a twelve-month prevalence of 13.9% in the
United States [2] and around 7% in Europe, where preva-
lence differs over a wide range between countries [3].
More than 80% of people suffering from AUD do not
receive formal treatment [2], and of those who do, only
25–43% remain abstinent [4, 5]. To increase the efficacy
of AUD treatment, novel treatment approaches are needed
which would optimally be designed as modules that can
flexibly be administered in personalized multimodal treat-
ment programs.
The progress of basic neuroscientific knowledge about
alcohol addiction and advances in methodology now make
neuroscience-based treatment approaches like transcranial
magnetic stimulation (TMS) [6–9], transcranial direct
current stimulation (tDCS) [10–13], deep brain stimu-
lation (DBS) [14, 15], and real-time functional magnetic
resonance neurofeedback (rtfMRI NFB) [16–18] available,
which are able to target disease-related brain regions and
brain processes with more or less precision.
One process that has prominently been linked to AUD
and is a promising aim for targeted neuroscience-based
interventions is the cue-reactivity response [19–22], the
reaction to the presentation of alcohol-related stimuli,
e.g. pictures, odors, or taste of alcoholic beverages. In the
brain, core regions associated with cue-reactivity are the
ventral striatum (VS), the anterior cingulate cortex (ACC),
and the ventromedial prefrontal cortex (vmPFC) [23, 24].
Reviewing the cognitive neuroscience literature on behav-
ioral change in AUD, Naqvi & Morgenstern [25] concluded
that enhanced reactivity of the ventral striatum to alcohol
and alcohol-related cues together with impairments in pre-
frontal control regions are the major factors responsible
for maintaining AUD. Along these lines, Becker et al. [26]
have recently demonstrated enhanced striatal reward sensi-
tivity and impairments in prefrontal-striatal connectivity in
patients with AUD in a monetary reward task, hinting
at a more generalized impairment in reward processing
in AUD, which has also been found being predictive for
neural changes during psychotherapeutic treatment [27].
To target the cortical and subcortical processes involved
in cue-reactivity and cognitive control, real-time fMRI
Neurofeedback is a promising approach. In rtfMRI NFB
participants are shown a near real-time feedback signal
indicating a specific brain process while they are lying
in an MR scanner and are instructed to influence this
feedback signal in a desired direction (see Fig. 2 for an
illustration). In contrast to other treatment approaches
like pharmacological interventions, TMS, or DBS, in rtfRMI
NFB patients are actively engaging to influence a brain
process, which might have additional psychological thera-
peutic benefits by promoting self-efficacy and self-regulation
[28]. Furthermore, in comparison, rtfMRI NFB offers a
relatively high spatial acuity, especially in subcortical brain
regions.
While rtfRMI NFB treatment is a relatively new tool in
psychiatry, first results are promising. Initial evidence has
been presented that rtfRMI NFB has effects for example in
major depressive disorder [29–34], schizophrenia [35–37],
attention deficit hyperactivity disorder [38, 39], phobia [40],
autism [41], posttraumatic stress disorder [42], and Border-
line personality disorder [43].
With regard to substance use disorders, rtfMRI NFB
has been mainly explored in the treatment of nicotine
addiction [44]. Several studies have demonstrated a reduc-
tion of nicotine craving through NFB [45–48]. Interest-
ingly, a recent study has found that including functional
connectivity information in the feedback signal leads to a
higher reduction of nicotine craving [49].
So far, only few studies have been conducted to assess
the use of rtfRMI NFB as an interventional tool in AUD.
Showing that neurofeedback training with feedback from
individually chosen cortical regions was able to reduce
craving in patients with AUD directly after neurofeed-
back training, Karch et al. [50] demonstrated the feasi-
bility of neurofeedback interventions in AUD. In a study
with non-treatment seeking heavy social drinkers, Kirsch et
al. [18] found that participants who received real feedback
in comparison to a yoked feedback group and a sham con-
trol group were able to learn to downregulate their ventral
striatum activation during presentation of pictures of alco-
holic beverages. They could further show that downregula-
tion of the VS was correlated with activation in the right
inferior frontal gyrus in the real feedback group, which is in
accordance with the model of Naqvi & Morgenstern [25].
In the Systems Biology of Alcohol Addiction (SyBil-AA)
rtfRMI NFB study we are now testing whether neurofeed-
back training will have beneficial effects in heavily impaired
AUD patients in a clinical setting. The results of this study
will provide insights into the efficacy of NFB training in
AUD, the involved brain systems, and might help to identify
predictors of treatment success which could potentially be
useful in developing personalized treatment approaches.
Methods/Design
To investigate the effect of rtfMRI NFB and identify the
underlying neural mechanisms we will include N = 100
patients with a diagnosis of alcohol use disorder recruited
from the outpatient and inpatient clinics of the Department
of Addiction Behavior and Addiction Medicine at the
Central Institute of Mental Health (CIMH), Mannheim,
Germany. Participants will be randomly assigned to one
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of 5 parallel groups. All groups will receive true rtfMRI
NFB from different brain processes and will be followed
up monthly for three months (Fig. 1).
Participant eligibility and recruitment
Eligible participants are between 18 and 65 years with
normal or corrected-to-normal vision. They are diagnosed
with alcohol dependence according to the International
Classification of Diseases, tenth edition (ICD-10: F10.2)
with controlled abstinence for at least 5 and a maximum
of 21 days prior to study inclusion. Additionally, a medic-
ally supervised detoxification program (treatment of with-
drawal symptoms with short-acting benzodiazepines or
clomethiazole) has to have been completed for at least
3 days.
Exclusion criteria are: meeting the criteria of any axis I
psychiatric disorder according to the Diagnostic and Statis-
tical Manual of Mental Disorders, fourth edition (DSM-IV)
and the ICD-10 within the past 12 months, with the excep-
tion of alcohol and nicotine abuse/dependence and a
mild depression related to alcohol consumption or de-
toxification. Further exclusion criteria are a positive
urine drug screening, current use of psychotropic or
anticonvulsive medications, epilepsy or neurological or
severe medical illness, suicidal tendencies, pregnancy,
and breastfeeding.
For recruitment, participants are informed by a psycholo-
gist of the study team about the study purpose and are able
to ask all questions concerning the study content. Partici-
pants are then asked to provide written informed consent
before being screened for in- and exclusion criteria. Partici-
pants are able to withdraw their consent at any time.
Screening assessment & group allocation
Screening for in- and exclusion criteria includes the
Structured Clinical Interview for DSM-IV (SKID-I) [51]
conducted by a clinical psychologist. Either during the
detoxification program or the screening assessment a
drug and pregnancy test is conducted. Please see Table 1
for further information on the schedule of measurements.
Participants who meet inclusion criteria are randomly
assigned to one of five groups: three experimental and
two control groups, respectively. Each group has to fulfil
different tasks with either downregulating the ventral
striatum, upregulating the right inferior frontal gyrus
(rIFG), increasing the connectivity (negative correlation)
between rIFG and VS, downregulating the auditory cor-
tex (downregulation control) or upregulating the audi-
tory cortex (upregulation control). The auditory cortex
was chosen as control region because it is not involved
in cue-reactivity [22].
Group allocation of included participants is conducted
by the study team with a computer-generated random
list based on the sequence of inclusion. No stratification
factors are used in the allocation process.
Baseline assessment
After group allocation, all participants take part in a base-
line assessment about demographic questions, alcohol use,
actual medication, personality, and clinical symptoms (see
Table 1). In addition, participants conduct the computer-
based Incentive Conflict Task (ICT, [52]) during the base-
line assessment.
Neurofeedback setup
rtfMRI NFB is conducted at Siemens 3 T Tim Trio
scanners (Siemens Healthineers, Erlangen, Germany) at
the Central Institute of Mental Health in Mannheim,
Germany. Each participant receives neurofeedback training
on three scanning days within a period of two weeks. On
each day a 5:21 min T1-weighted anatomical MPRAGE
scan, a 12:00 min functional resting state scan with eyes
closed, and three neurofeedback runs of 9:29 min are con-
ducted. At the beginning of each session an MPRAGE
image is acquired with a time of repetition (TR) of 2.3 s, an
echo time (TE) of 3.03 ms, 9° flip angle, a field of view of
256 mm with 192 sagittal slice, a matrix size of 256 × 256
mm, 1x1x1 mm voxel size, and GRAPPA with iPAT = 2.
Resting state and NFB sessions are scanned with echo-
planar imaging (EPI) sequences with a TR of 1.64 s, a TE
of 30 ms, 73° flip angle, a field of view of 192 mm, 3x3x3
Fig. 1 Study flow chart. N = 100 patients with a diagnosis of alcohol addiction from the local inpatient and outpatient addiction clinics are
randomized to 5 single-blind groups, receive rtfMRI NFB treatment on 3 days within two weeks, and are followed up monthly for 3 months
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mm voxel size, 33 slices of 3 mm thickness with a dis-
tance factor of 33%, and GRAPPA with iPAT = 2.
During NFB scans, reconstructed DICOM images are
transferred from the imaging computer to a laptop that
preprocesses the images and extracts the neurofeedback
signal by means of an in-house software. The feedback
value is then send to a presentation computer and shown
to the participant in the scanner as a thermometer
value besides the picture of an alcoholic beverage pre-
ferred by the participant (beer, wine, or both). See Fig. 2
for an illustration. The thermometer is updated with every
new volume. The order of pictures is randomized between
participants.
rtfMRI NFB is conducted with in-house MATLAB
(MathWorks Inc., Sherborn, MA, USA) scripts based
on SPM8 functions (Wellcome Department of Cognitive
Neurology, London, UK), and Presentation software (Neu-
robehavioral Systems, Inc., Albany, CA, USA) to present
pictures and the feedback signal. On each scanning day,
the acquired anatomical image is first segmented and nor-
malized to MNI standard space. The inverse deformations
of the normalization are then applied to warp the masks
of the target regions into subject space.
During rtfMRI NFB scanning, functional images are rea-
ligned to the mean of the first 10 functional images and
resliced. Then, the mask images are resampled to the space
Table 1 Schedule of measurements conducted in the study
Measurement Sa T0a MRI1a MRI2a MRI3a FU1/2b FU3a
Sociodemographic information X
Structured Clinical Interview (SKID – I) X
Drinking Assessment Interview (Form 90) X
Blood sample (AUD-related markers) X X
Urine sample (pregnancy, drugs) X
Current medication X Xc Xc
Current smoking behavior Xc Xc Xc Xc Xc Xc
Breath alcohol test X
Current drug use Xc Xc
Incentive Conflict Task X
Clinical & Personality Questionnaires
Edinburgh Inventory of Handedness X
Beck Depression Inventory X
State Trait Anxiety Inventory X
Behavioral Inhibition/Approach System X
Barratt Impulsiveness Scale X
Fagerstrøm Test of Nicotine Dependence X
Alcohol-Related Questionnaires
Quick Drinking Assessment Interview (Form 90-AQ) X X
Alcohol Dependence Scale X
Alcohol Abstinence Self-Efficacy Scale X X X
German Inventory of Drinking Situations X
Obsessive Compulsive Drinking Scale X X X
Alcohol Urge Questionnaire X X X
Craving-Automatized-Scale-Alcohol X X X
MRI
Anatomical image (MPRAGE) X X X
Resting state X X X
Neurofeedback X X X
Transfer run X X
Craving (visual analog scale) pre & post scanning X X X
Perceived control over NFB (visual analog scale) X X X
S screening assessment, T0 baseline assessment, MRI rtfMRI scanning days, FU monthly follow-up. aface-to-face; bvia telephone; cself-reported (if unclear)
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of the current image and mean intensity values from the
voxels in the target regions are extracted.
For activation NFB, intensity values during presentation
of alcohol images are averaged over the last three volumes
(moving average) to stabilize the feedback signal and per-
cent signal change with regard to the preceding fixation
cross block is calculated. The scale of the feedback therm-
ometer is adaptively adjusted to the maximum absolute
signal change and the feedback signal is presented to the
participant.
For connectivity NFB, partial correlations between the
intensity values of the VS and right IFG adjusted for the
cerebro-spinal fluid signal over the last 15 volumes are
used to calculate the feedback signal. Again, the scale of
the feedback thermometer is adaptively adjusted to the
maximum absolute value reached. In this exploratory
group, the goal of the intervention is to increase the
inhibiting influence of the rIFG to the VS and the partici-
pants are instructed to downregulate the depicted process.
However, a negative correlation between VS and rIFG
could arise from the desired state, but also from an inverse
behavior of the system with increased VS and diminished
frontal activity. To enforce the top-down inhibitory state of
the system we included the additional constraints in the
connectivity feedback that the VS should be downregulated
and the rIFG should be upregulated and switch negative
feedback values to positive if these constraints are not met.
Task design
NFB sessions have a block design with alternating pres-
entation of a fixation cross (baseline; 41 s) and a picture
of a preferred alcoholic beverage (beer, wine, or both;
approx. 51 s), each for 6 times. Approximately 10 s after
onset of the alcoholic pictures a feedback thermometer
is shown on both sides of the picture and updated every
TR (feedback; 41 s). On the first and third day, the last
(third) run is conducted as a transfer run without pres-
entation of the feedback signal (Fig. 3).
On each scanning day participants rate their craving
on a visual analog scale directly before and after scan-
ning. After completing the third MRI scanning session,
participants are asked to answer alcohol-related ques-
tionnaires (see Table 1).
Follow-up assessments
Follow-up assessments take place monthly after the last
MRI session over a period of three months. At the first
two time points participants are contacted by phone and
asked about their current medication, their abuse of
tobacco, nicotine and drugs and a potential alcohol relapse
(see Table 1). Three months after the last MRI session, pa-
tients are invited to a final appointment at the CIMH. Dur-
ing this session, blood samples are collected and participants
are asked about substance use and answer alcohol-related
questionnaires (see Table 1). For the final appointment, pa-
tients receive a monetary compensation of 50 €.
Statistical analyses
As primary outcome analysis we will conduct group com-
parisons of relapse rates with survival analysis and assess
reduction of alcohol intake during the follow-up phase. As
secondary and exploratory outcome measures we will
Fig. 2 Real-time fMRI neurofeedback setup. Acquired images are reconstructed and send to a laptop running in-house MATLAB (MathWorks Inc.,
Sherborn, MA, USA) scripts based on SPM8 (Wellcome Department of Cognitive Neurology, London, UK) functions to preprocess the images and
extract the neurofeedback signal. The feedback value is send to a computer running Presentation software (Neurobehavioral Systems, Inc., Albany,
CA, USA) and presented to the participant in the scanner as a thermometer value besides a picture of an alcoholic beverage
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assess whether rtfMRI NFB reduces alcohol craving during
the NFB sessions, how brain activation and brain connect-
ivity changes within and between the sessions, whether
functional or structural MRI markers can be identified that
predict neurofeedback learning and the success of the inter-
vention, and whether differences in efficacy of the group-
specific interventions do exist.
To analyze the effects of rtfMRI NFB, offline data analysis
will be conducted with MATLAB and SPM. Data prepro-
cessing will consist of slice-time correction, realignment,
segmentation of the anatomical image, normalization to the
MNI space, smoothing, and identification of outlier
volumes with excessive head motion. The preprocessed
data will be used in first level single subject analyses in
which the time courses of the experimental conditions
will be convolved with the canonical hemodynamic re-
sponse function and used in a general linear model to esti-
mate brain responses during rtfMRI NFB. Then, first level
results will be used in second level group comparisons to
estimate differential activation between groups, test for as-
sociations with clinical variables, and assess the predictive
value of imaging markers for the future course of the dis-
ease. Additionally, large-scale adaptations in functional
networks during rtfMRI NFB will be assessed by whole-
brain psychophysiological interaction analysis [53].
Depending on the type of the data, missing data will
either be left out from the analyses (e.g. fMRI data), or
imputed (e.g. missing questionnaire items).
Power calculations
Power calculations were conducted with the G*Power
software package [54]. In the clinical analysis (follow-up
measures) the power for detecting group differences at
p < .05 under the assumption of a medium effect size
(Cohen’s d = .5) is 78% with two sample t-tests when
treatment (n = 60) and control groups (n = 40) are pooled.
Assuming an effect size of f = .61 as observed for the neu-
rofeedback effect on VS reduction in our pilot study [18],
the neurofeedback analyses based on an ANOVA repeated
measures model with a group x time contrast has a power
of 89% in the VS and of 88% in the rIFG to detect FWE
(Bonferroni) corrected significant results in the respective
ROI analyses.
Data management and dissemination
To ensure data quality, questionnaires are automatically
scanned and entered into the study data base. Data man-
agement and monitoring is conducted by the study team.
Study data will be stored on servers of the Central Institute
of Mental Health separated from personal information of
the participants. At the end of the study personal informa-
tion will be deleted. The procedures comply with German
data privacy laws. We will conduct interim analyses on the
acquired data to present the study to scientific audiences
(e.g. at conferences, meetings, etc.) during the data acquisi-
tion phase. Results of the final analyses will be published in
scientific journals and presented on scientific conferences.
Authorship will be defined in accordance to the German
Research Foundation’s recommendations for safeguarding
good scientific practice [55]. Study conduct is reported and
audited in interim and final reports of the SyBil-AA consor-
tium to the funding agency.
Discussion
In the Systems Biology of Alcohol Addiction (SyBil-AA)
rtfRMI NFB study we are assessing the efficacy of rtfRMI
NFB on ventral striatal cue-reactivity and frontal control
processes in the treatment of alcohol use disorder. To the
best of our knowledge, the study is one of two ongoing
clinical trials of rtfMRI NFB in AUD (see Cox et al. [56]
for a description of the other trial), and will contribute to
the understanding of the use of rtfMRI NFB as a clinical
application in the context of a clinical treatment program
for AUD.
Besides the primary goal of testing clinical effects, the
study will provide data which will be useful to investi-
gate how rtfMRI NFB is leading to changes in the brain,
whether intervention success can be predicted by means
of neurobiological signatures and clinical variables, and
for which patients rtfMRI might be beneficial. Since we
Fig. 3 Experimental design. Design of neurofeedback (left) and transfer (right) tasks. Each run consists of 6 repetitions of the displayed sequences.
The last (third) runs on the first and third scanning day are conducted as transfer sessions without the neurofeedback signal. TR: Time of Repetition
(1 TR = 1.64 s)
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focus on ventral striatal activation to alcohol cues and
its prefrontal control, it could be expected that particularly
those patients will profit from the intervention that show
substantial ventral striatal cue reactivity to alcohol cues
prior to the intervention as it has been shown for other
treatments before [57]. However, it has been shown that
AUD is often associated with a shift of cue reactivity from
ventral to dorsal striatum [58]. For those patients, showing
a more habit like addiction behavior, instead of the ventral
striatum, the dorsal striatum might be an interesting
target for NFB interventions in AUD. Nevertheless, there is
no doubt, that prefrontal control regions play a central role
in craving and relapse [25]. Therefore, it could be specu-
lated that patients receiving a PFC upregulation feedback
might benefit from the NF treatment even if they do not
show strong ventral but increased dorsal striatal activation
to alcohol related cues.
An innovative condition in the present study is the
connectivity feedback condition. It has been shown in
the context of nicotine addiction that adding connectivity
information to the feedback signal increases efficiency
[49] and reduces cigarette craving but this has neither
been shown for alcohol patients nor with respect a long-
term outcome of a treatment.
However, the results from Kirsch et al. [18] could also
imply that a critical factor for the treatment effect could
be whether patients get the impression that they are able
to actively control their own brain response to alcohol
cues. Since patients can assume that the intention of the
training is the reduction of alcohol cue associated craving,
they might apply strategies to reduce this craving and, ac-
cordingly, to downregulate the feedback signal. Kirsch et al.
[18] showed that successful VS downregulation was accom-
panied by the application of specific cognitive strategies,
which might have let to the concurrent increase of pre-
frontal activation, although this activation was not fed
back to the participants. Thus, the direction of the signal
modulation could be a critical point in NFB, and patients
receiving the downregulation instruction might show more
effects than those receiving the upregulation instruction.
Future studies could further elaborate the effect of in-
struction by converting the feedback signal in upregulation
conditions and instructing all participants to downregulate
the signal, which from our experience seems to be the
natural direction expected by patients in a cue-reactivity
addiction context. This would also allow blinding the
patients completely, not only with respect to the group
(experimental vs. control) but also the kind of regula-
tion they are expected to apply.
The study could also reveal additional mechanistic infor-
mation about the mode of action of rtFMRI NF. Import-
antly, we conduct fMRI scans with whole-brain coverage,
which will allow us to investigate the role of other brain re-
gions like amygdala, insula cortex, or ventromedial PFC
which were not directly targeted with NFB in our study but
play important roles alcohol-related cue-reactivity [23, 24].
Another interesting aspect which might have an influence
on the results is the type of control for neurofeedback (see
e.g. [59]). We chose an active type of control in the NFB
study in which participants from the control group receive
a real feedback signal from a control region, which in our
case is the auditory cortex that is not involved in cue-
reactivity [22]. Other possibilities would be to use a control
group without feedback, a group that just views feedback
signal of other participants without instructions, or a yoke-
control group that is told to regulate the process but
receives feedback from another person. For task compar-
ability we decided against the first two options, and for
ethical reasons a yoke-control group in which participants
would receive fake instructions is questionable. Our
active-control groups will lead to results based on specific
target brain processes, and not per se on brain regulation
through NFB. However, differences between groups might
still be related to differences in regulation difficulty.
There are some shortcomings of the protocol. First, the
study is only single-blind. The staff members must prepare
the individual feedback set up (definition of ROI, definition
of direction) and are therefore not blinded. In future
studies, a double-blind protocol could be implemented
by separating staff that prepares the individual NF setup
and staff that instructs the participants. However, we think
it is worth to test the general applicability of rtfMRI NF to
AUD patients before setting up such an extensive study
protocol. Second, the study was retrospectively registered
in the German Clinical Trials Register (DRKS00010253;
WHO Universal Trial Number (UTN): U1111–1181-4218).
Due to fast inclusion of the first patient, registration was
conducted shortly after the begin of the study, but before
any data was processed or analyzed (Inclusion of first pa-
tient: 03/30/2016; application for registration: 04/26/2016;
registration date: 05/10/2016). However, the registration
complies with the goals of the study described in the grant
proposal and the study protocol will not be altered during
the study. Finally, we have not defined stopping criteria,
because we do not expect side effects besides those that
can be expected from fMRI scanning, which is a safe and
well-established technique. However, the principle investi-
gators will decide whether to continue or terminate the
study or specific parts of it if side effects were reported by
the participants.
Overall, the study is well suited to provide valuable
data on the efficacy of rtfMRI NFB as an add-on treat-
ment for AUD in a clinical setting. Furthermore, the
large amount of imaging data collected on the three
scanning days will be helpful to better understand how
rtfMRI NFB is working, and to identify factors that pre-
dict its clinical effects and could potentially be useful for
developing personalized treatment approaches.
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